Summary
Cardiovascular effects of the irreversible MAO-A inhibitor clorgyline and reversible MAO-inhibitors, moclobemide and brofaromine, were compared in the anesthetized rat. Electrical activity of the sympathetic renal nerve was monitored as an index of central sympathetic output. A long lasting decrease in the recorded parameters: blood pressure (BP), renal nerve activity (RNA) and heart rate (HR) was produced by acute administration of clorgyline (2 mg/Kg, IP). Acute treatment with moclobemide (10 mg/Kg, IP) or brofaromine (10 mg/Kg, IP) caused only a transient decrease in RNA. Pretreatment with the α2 antagonist yohimbine, decreased significantly the inhibitory effect of clorgyline on all three parameters. The selective α2 antagonist CH-38083 blocked the sympathoinhibitory effect of brofaromine. These results indicate an α2 adrenoceptor involvement in the central sympathoinhibitory effect of MAO inhibitors, which may be manifested as a hypotensive effect, including orthostatic hypotension, in patients treated with irreversible selective MAO inhibitors.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ashkenazi R, Finberg JPM, Youdim MBH (1983) Effect of LM5008, a selective inhibitor of 5-hydroxy-tryptamine uptake, in blood pressure and responses to sympathomimetic amines. Br J Pharmacol 79: 915–922.
Brown DL, Guyenet PG (1984) Cardiovascular neurons of brain stem with projections to the spinal cord. Am J Physiol 247: R1009–1016.
Coote JH, Dalton DW, Feniuk FW, Humphrey PP (1987) The central site of sympathoinhibitory action of 5-hydroxy tryptamine in the cat. Neuropharmacology 26: 147–154.
Da Prada M, Kettler R, Burkard WP, Haefely WE (1984) Moclobemide, an antidepressant with short-acting MAO-A inhibition: brain catecholamines and tyramine pressor effects in rats. In: Tipton KF, Dosiert P, Strolin-Benedetti M (eds) Monoamine oxidase and disease. Prospect for therapy with reversible inhibitors. Academic Press, London, pp 137–154.
Da Prada M, Kettler R, Keller HH, Burkard WP, Muggli-Maniglio D, Haefely WE (1989) Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther 248: 400–414.
Denney RM, Denney CB (1985) An update on the identity crisis of monoamine oxidase: new and old evidence for the independence of MAO A and MAO B. Pharmacol Ther 30: 227–259.
Finberg JPM, Youdim MBH (1983) Selective MAO A and B inhibitors: their mechanism of action and pharmacology. Neuropharmacology 22: 441–446.
Finberg JPM, Youdim MBH (1988) Potentiation of tyramine pressor responses in conscious rats by reversible inhibitors of monoamine oxidase. J Neural Transm [Suppl] 26: 11–16.
Fozard JR, Mir AK, Middlemiss DN (1987) Cardiovascular response to 8-hydroxy-2-(di-n-propylamino) tetraline (8-OH-DPAT) in the rat: site of action and pharmacological analysis. J Cardiovasc Pharmacol 9: 328–347.
Fuentes JA, Ordaz A, Neff NH (1979) Central mediation of the antihypertensive effect of pargyline in spontaneous hypertensive rats. Eur J Pharmacol 57: 21–27.
Gasic S, Korn A, Eichler HC, Oberhummer I, Zapotoczky HG (1983) Cardiocirculatory effects of moclobemide (RO 11-1163), a new reversible, short acting MAO-inhibitor with preferential type A inhibition, in healthy volunteers and depressive patients. Eur J Clin Pharmacol 25: 173–177.
Goridis C, Neff NH (1971) Monoamine oxidase in sympathetic nerves: a transmitter specific enzyme type. Br J Pharmacol 43: 814–818.
Graefe K-H, Boenisch H, Trendelenburg U (1971) Time-dependent changes in neuronal net uptake of noradrenaline after pretreatment with pargyline and/or reserpine. Naunyn Schmiedebergs Arch Pharmacol 271: 1–28.
Guyenet PG, Haselton JR, Sun MK (1989) Sympathoexcitatory neurons of the rostroventral medulla and the origin of the sympathetic vasomotor tone. In: Cirielo J, Caverson MM, Polosa C (eds) Progress in brain research, vol 91. Elsevier, p 105.
Haefely W, Burkard WP, Cesura AM, Kettler R, Lorez HP, Martin JR, Richards JG, Scherschlicht R, Da Prada M (1992) Biochemistry and pharmacology of moclobemide, a prototype RIMA. Psychopharmacology 106: S6–S14.
Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17: 614–627.
Korn A, Da Prada M, Raffesberg W, Gasic S, Eichler HG (1988) The effect of moclobemide, a new reversible monoamine oxidase inhibitor, on absorption and pressor effect of tyramine. J Cardiovasc Pharmacol 11: 17–23.
Kuhn DM, Wolf WA, Lovenberg W (1980) Review of the role of central serotonergic neural system in blood pressure regulation. Hypertension 2: 243–255.
Lavian G, Dibona G, Finberg JPM (1991) Inhibition of sympathetic nerve activity by administration of the tricyclic antidepressant desipramine. Eur J Pharmacol 194: 153–159.
McCall RB, Harris LT, King KA (1991) Sympatholytic action of yohimbine mediated by 5-HT1A receptors. Eur J Pharmacol 199: 263–265.
Moeller HJ, Wendt G, Waldmeier P (1991) Brofaromine — a selective, reversible and short-acting MAO-A inhibitor: Review of the pharmacological and clinical findings. Pharmacopsychiatry 24: 50–54.
Neff NH, Goridis C (1972) Neuronal monoamine oxidase: specific enzyme types and their rate of formation. In: Costa E, Sandler M (eds) Monoamine oxidase and the monoamine oxidase inhibitor drugs—new vistas. Raven Press, New York, p 307.
Neff NH, Yang NYT (1974) Another look at the monoamine oxidase inhibitor drugs. Life Sci 14: 2061–2074.
Neff NH, Yang HYT, Fuentes JA (1974) The use of selective monoamine metabolism in brain. In: Usdin E (eds) Neuropharmacology of monoamines and their regulatory enzymes. Raven Press, New York, p 49 (Adv Biochem Psychopharmacol, vol 12).
Paton DM (1973) Mechanisms of efflux of noradrenaline from adrenergic nerves in rabbit atria. Br J Pharmacol 49: 614–627.
Takahashi H (1985) Cardiovascular and sympathetic response to intracarotid and intravenous injection of serotonin in rats. Arch Pharmacol 329: 222–226.
Vizi ES, Harsing LG JR, Gaal J, Kapocsi J, Bernath S, Somogyi GT (1986) CH-38083, a selective, potent antagonist of alpha-2 adrenoceptors. J Pharmacol Exp Ther 238: 701–706.
Waldmeier PC, Staecklin K (1989) The reversible MAO inhibitor, brofaromine, inhibits serotonin uptake in vivo. Eur J Pharmacol 169: 197–204.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer-Verlag
About this paper
Cite this paper
Lavian, G., Finberg, J.P.M., Youdim, M.B.H. (1994). Comparison of the effect of reversible and irreversible MAO inhibitors on renal nerve activity in the anesthetized rat. In: Tipton, K.F., Youdim, M.B.H., Barwell, C.J., Callingham, B.A., Lyles, G.A. (eds) Amine Oxidases: Function and Dysfunction. Journal of Neural Transmission, vol 41. Springer, Vienna. https://doi.org/10.1007/978-3-7091-9324-2_14
Download citation
DOI: https://doi.org/10.1007/978-3-7091-9324-2_14
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-82521-1
Online ISBN: 978-3-7091-9324-2
eBook Packages: Springer Book Archive